<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541888</url>
  </required_header>
  <id_info>
    <org_study_id>ZKY-CSA-202001</org_study_id>
    <nct_id>NCT04541888</nct_id>
  </id_info>
  <brief_title>Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of CsA ophthalmic gel in the&#xD;
      treatment of moderate to severe dry eye disease .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter,randomized, double-blind, vehicle-controlled Study.Subjects will be randomly&#xD;
      assigned to the experimental group and the control group,experimental group: CsA eye gel: 0.3&#xD;
      g: 0.15 mg, once daily;One drop into each eye when you use it.hypromellose eye&#xD;
      drops:10ml：50mg,three times a day Control group: vehicle. One drop into the eye, once&#xD;
      daily;One drop into each eye when you use it.hypromellose eye drops:10ml：50mg,three times a&#xD;
      day&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients whose corneal fluorescein staining score (ICSS) decreased by ≥1 point from baseline at visit 5 (study eye)</measure>
    <time_frame>84 days after admission</time_frame>
    <description>ICSS：no staining = 0，few/rare punctate lesions = 1，discrete and countable lesions = 2，lesions too numerous to count，but not coalescent = 3，coalescent = 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EDS score at the NO.3, NO.4 and NO.5 visit was compared with the baseline EDS score (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>0-100 points VAS score was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average changes in VAS scores of 6 dry eye symptoms (burning/needling sensation, pruritus, foreign body sensation, discomfort, photophobia and pain) at the NO.3, NO.4 and NO.5 visit were compared with baseline (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>0-100 points VAS score was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal fluorescein staining score (ICSS)at the NO.3, NO.4 and NO.5 visit was compared with the baseline (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>ICSS：no staining = 0，few/rare punctate lesions = 1，discrete and countable lesions = 2，lesions too numerous to count，but not coalescent = 3，coalescent = 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxford score at the NO.3, NO.4 and NO.5 visit was compared with the baseline (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>0~V grade was evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUT at the NO.3, NO.4 and NO.5 visit was compared with the baseline (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer at the NO.3, NO.4 and NO.5 visit was compared with the baseline (binocular)</measure>
    <time_frame>14 days after admission ，42 days after admission ，84days days after admission</time_frame>
    <description>Basal tear secretion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">644</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA Ophthalmic Gel</intervention_name>
    <description>The CsA eye gel of 0.3 g: 0.15 mg</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CsA gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypromellose Eye Drop</intervention_name>
    <description>Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>zhenshishuang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1）18≤Age≤80, both male and female 2）According to the symptoms and signs and ophthalmologic&#xD;
        examinations, the patients were diagnosed as moderate to severe dry eye&#xD;
&#xD;
          1. EDS score is more than 40 points;&#xD;
&#xD;
          2. BUT is less than 10 s;&#xD;
&#xD;
          3. Schirmer test result is less than 10mm/5 min;&#xD;
&#xD;
          4. ICSS≥2 points. 3）The ICSS score of baseline decreased by≤ 20% compared with that of&#xD;
             screening period 4）Agree to participate in the study and voluntarily sign informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe dry eye patients requiring surgical treatment&#xD;
&#xD;
          2. Had inner eye surgery within 12 months prior to screening or required inner eye&#xD;
             surgery during the study period;Eyelid surgery was performed within 6 months prior to&#xD;
             screening&#xD;
&#xD;
          3. Patients receiving permanent lacrimal insertion or patients receiving temporary&#xD;
             lacrimal insertion within 6 months prior to screening;&#xD;
&#xD;
          4. Operation-induced dry eye&#xD;
&#xD;
          5. Glaucoma patients;&#xD;
&#xD;
          6. Unwilling to avoid wearing contact lenses;&#xD;
&#xD;
          7. Systemic inflammation or active eye infection and blepharitis;&#xD;
&#xD;
          8. Patients with multiple episodes of viral keratitis&#xD;
&#xD;
          9. Patients with ocular cicatricial pemphigoid, obvious conjunctival scar, ocular&#xD;
             chemical burn and neurotrophic keratoconjunctivitis&#xD;
&#xD;
         10. Patients with malignant tumors in the past 5 years, except the thoroughly cured basal&#xD;
             cell carcinoma of skin, squamous cell carcinoma in situ of skin, and primordial&#xD;
             cervical cancer;&#xD;
&#xD;
         11. Perimenopausal women are taking hormone replacement therapy&#xD;
&#xD;
         12. Patients who cannot stop using other eye drops and other ophthalmic preparations&#xD;
             during the study period;&#xD;
&#xD;
         13. Patients with severe cardiopulmonary diseases, uncontrolled hypertension and diabetes,&#xD;
             etc. that affect the collection or compliance of study parameters;&#xD;
&#xD;
         14. ALT and AST ≥ 2 times of the normal upper limit, and serum creatinine ≥ 1.5 times of&#xD;
             the normal upper limit&#xD;
&#xD;
         15. With a history of central nervous system disease or epilepsy, and/or a mental state&#xD;
             that does not cooperate&#xD;
&#xD;
         16. Pregnant women and lactating women, or women of childbearing age, do not adopt&#xD;
             effective contraceptive measures;&#xD;
&#xD;
         17. Participated in other clinical trials or participated in other clinical trials within&#xD;
             1 months before the election;&#xD;
&#xD;
         18. Systemic or topical cyclosporine drugs within 1 months before the election;&#xD;
&#xD;
         19. Allergy to CsA, fluorescein or any component of the drug is known；&#xD;
&#xD;
         20. Patients who were not considered suitable for the study, including those who were&#xD;
             unable or unwilling to comply with the protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shiyou zhou, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Ophthalmological Center of Zhongshan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shiyou zhou, PHD</last_name>
    <phone>020-87334687</phone>
    <email>gdeyeb@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yanjie yan, master</last_name>
    <phone>020-66610729</phone>
  </overall_contact_backup>
  <results_reference>
    <citation>Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010 Oct;18(5):352-61. doi: 10.3109/09273948.2010.498657. Review.</citation>
    <PMID>20735287</PMID>
  </results_reference>
  <results_reference>
    <citation>Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002 Mar;120(3):330-7. Erratum in: Arch Ophthalmol 2002 Aug;120(8):1099.</citation>
    <PMID>11879137</PMID>
  </results_reference>
  <results_reference>
    <citation>Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005 Jan;24(1):80-5.</citation>
    <PMID>15604871</PMID>
  </results_reference>
  <results_reference>
    <citation>Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006 Feb;25(2):171-5.</citation>
    <PMID>16371776</PMID>
  </results_reference>
  <results_reference>
    <citation>Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue JS, Ismail D, Sainz-de-la-Maza M, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019 Jan;103(1):125-131. doi: 10.1136/bjophthalmol-2017-311801. Epub 2018 Mar 15.</citation>
    <PMID>29545413</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009 Feb;147(2):206-213.e3. doi: 10.1016/j.ajo.2008.08.015. Epub 2008 Oct 9.</citation>
    <PMID>18848318</PMID>
  </results_reference>
  <results_reference>
    <citation>Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27.</citation>
    <PMID>28079022</PMID>
  </results_reference>
  <results_reference>
    <citation>Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11.</citation>
    <PMID>26365210</PMID>
  </results_reference>
  <results_reference>
    <citation>Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003 Oct;22(7):640-50. Review.</citation>
    <PMID>14508260</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

